cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Xilio Therapeutics Inc
1 own
3 watching
Current Price
$3.62
$-0.11
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
99.21M
52-Week High
52-Week High
14.86
52-Week Low
52-Week Low
1.95
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization99.21M
icon52-Week High14.86
icon52-Week Low1.95
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Xilio Therapeutics Inc do?
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Read More
How much money does Xilio Therapeutics Inc make?
News & Events about Xilio Therapeutics Inc.
Globe Newswire
2 months ago
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, December 1, 2022, at 12...
Globe Newswire
2 months ago
XTX202, a tumor-activated IL2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND ...
Globe Newswire
3 months ago
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual ...
Globe Newswire
1 year ago
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selectiveimmuno-oncology therapiesforpatients with cancer,today announced data from preclinical studies of XTX301, an engineered tumor-selective interleukin-12 (IL-12) ...
Frequently Asked Questions
Frequently Asked Questions
What is Xilio Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Xilio Therapeutics Inc shares?
plus_minus_icon
How can I buy Xilio Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Xilio Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Xilio Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Xilio Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Xilio Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Xilio Therapeutics Inc?
plus_minus_icon
What percentage is Xilio Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Xilio Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.62
$-0.11
(-2.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00